145 related articles for article (PubMed ID: 10576529)
1. Prevention of type 2 diabetes: role of metformin.
Charles MA; Eschwège E
Drugs; 1999; 58 Suppl 1():71-3; discussion 75-82. PubMed ID: 10576529
[TBL] [Abstract][Full Text] [Related]
2. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
3. Metformin: diamonds are forever.
Papanas N; Maltezos E; Mikhailidis DP
Expert Opin Pharmacother; 2009 Oct; 10(15):2395-7. PubMed ID: 19678795
[TBL] [Abstract][Full Text] [Related]
4. Effect of weight change and metformin on fibrinolysis and the von Willebrand factor in obese nondiabetic subjects: the BIGPRO1 Study. Biguanides and the Prevention of the Risk of Obesity.
Charles MA; Morange P; Eschwège E; André P; Vague P; Juhan-Vague I
Diabetes Care; 1998 Nov; 21(11):1967-72. PubMed ID: 9802752
[TBL] [Abstract][Full Text] [Related]
5. Metformin therapy and clinical uses.
Scarpello JH; Howlett HC
Diab Vasc Dis Res; 2008 Sep; 5(3):157-67. PubMed ID: 18777488
[TBL] [Abstract][Full Text] [Related]
6. The effect of basal insulin glargine on the fibrinolytic system and von Willebrand factor in people with dysglycaemia and high risk for cardiovascular events: Swedish substudy of the Outcome Reduction with an Initial Glargine Intervention trial.
Rautio A; Boman K; Gerstein HC; Hernestål-Boman J; Lee SF; Olofsson M; Mellbin LG
Diab Vasc Dis Res; 2017 Jul; 14(4):345-352. PubMed ID: 28403644
[TBL] [Abstract][Full Text] [Related]
7. Soluble CD40 ligand, plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor-1-antigen in normotensive type 2 diabetic subjects without diabetic complications. Effects of metformin and rosiglitazone.
Yener S; Comlekci A; Akinci B; Demir T; Yuksel F; Ozcan MA; Bayraktar F; Yesil S
Med Princ Pract; 2009; 18(4):266-71. PubMed ID: 19494532
[TBL] [Abstract][Full Text] [Related]
8. Metformin as first choice in oral diabetes treatment: the UKPDS experience.
Holman R
Journ Annu Diabetol Hotel Dieu; 2007; ():13-20. PubMed ID: 18613325
[TBL] [Abstract][Full Text] [Related]
9. Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial.
De Jager J; Kooy A; Lehert P; Bets D; Wulffelé MG; Teerlink T; Scheffer PG; Schalkwijk CG; Donker AJ; Stehouwer CD
J Intern Med; 2005 Jan; 257(1):100-9. PubMed ID: 15606381
[TBL] [Abstract][Full Text] [Related]
10. Effects of 1-year treatment with metformin on metabolic and cardiovascular risk factors in non-diabetic upper-body obese subjects with mild glucose anomalies: a post-hoc analysis of the BIGPRO1 trial.
Fontbonne A; Diouf I; Baccara-Dinet M; Eschwege E; Charles MA
Diabetes Metab; 2009 Nov; 35(5):385-91. PubMed ID: 19665415
[TBL] [Abstract][Full Text] [Related]
11. Beneficial effects of metformin on haemostasis and vascular function in man.
Grant PJ
Diabetes Metab; 2003 Sep; 29(4 Pt 2):6S44-52. PubMed ID: 14502100
[TBL] [Abstract][Full Text] [Related]
12. An investigation into the pleiotropic activity of metformin. A glimpse of haemostasis.
Markowicz-Piasecka M; Sadkowska A; Huttunen KM; Podsiedlik M; Mikiciuk-Olasik E; Sikora J
Eur J Pharmacol; 2020 Apr; 872():172984. PubMed ID: 32017937
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial.
Schernthaner G; Matthews DR; Charbonnel B; Hanefeld M; Brunetti P;
J Clin Endocrinol Metab; 2004 Dec; 89(12):6068-76. PubMed ID: 15579760
[TBL] [Abstract][Full Text] [Related]
14. Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes.
Lund SS; Tarnow L; Frandsen M; Smidt UM; Pedersen O; Parving HH; Vaag AA
Eur J Endocrinol; 2008 Jan; 158(1):35-46. PubMed ID: 18166815
[TBL] [Abstract][Full Text] [Related]
15. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
Krentz AJ; Bailey CJ
Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
[TBL] [Abstract][Full Text] [Related]
16. Metformin: New Preparations and Nonglycemic Benefits.
Fujita Y; Inagaki N
Curr Diab Rep; 2017 Jan; 17(1):5. PubMed ID: 28116648
[TBL] [Abstract][Full Text] [Related]
17. Metformin, a promising oral antihyperglycemic for the treatment of noninsulin-dependent diabetes mellitus.
Wildasin EM; Skaar DJ; Kirchain WR; Hulse M
Pharmacotherapy; 1997; 17(1):62-73. PubMed ID: 9017766
[TBL] [Abstract][Full Text] [Related]
18. Metformin and vascular protection: a cardiologist's view.
Libby P
Diabetes Metab; 2003 Sep; 29(4 Pt 2):6S117-20. PubMed ID: 14502109
[TBL] [Abstract][Full Text] [Related]
19. Strategies for the management of diabetic dyslipidaemia.
Taskinen MR
Drugs; 1999; 58 Suppl 1():47-51; discussion 75-82. PubMed ID: 10576525
[TBL] [Abstract][Full Text] [Related]
20. Metformin: old wine in new bottle--evolving technology and therapy in diabetes.
Joshi SR
J Assoc Physicians India; 2005 Nov; 53():963-72. PubMed ID: 16515237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
